<DOC>
	<DOCNO>NCT02539316</DOCNO>
	<brief_summary>Parenteral nutrition ( PN ) part supportive care oncology Pediatric patient 's nutritional status justifies enteral impossible . In literature , hepatotoxicity , cholestasis type , standard emulsion soy oil-based ( type Médialipide® ) describe context long-term PN especially premature infant . It result increase gammaGT . The recent use lipid emulsion contain Omega 3 ( Smoflipid ) , study adult population preterm PN short long , find hepatoprotection . Investigators find single retrospective study Pediatric Onco-Hematology . No prospective study perform population Onco-Hematology . The objective study evaluate impact use SMOFlipid® parenteral nutrition early occurrence cholestasis compare Médialipides short-term use parenteral nutrition Onco-Hematology pediatric population .</brief_summary>
	<brief_title>Pilot Study : Hepatoprotective Role SMOFlipid® Used Short-term Parenteral Nutrition Onco-Hematology Pediatric Population</brief_title>
	<detailed_description />
	<criteria>018 year Solid Tumors hematological malignancy Requiring parenteral nutrition least 5 day With central catheter With normal hepatic function test Liver function test disrupt Patient tumor liver metastases Patient againstindication use lipid</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Parenteral Nutrition</keyword>
</DOC>